Aprinoia Therapeutics (Aprinoia Therapeutics) Common Stock : $4.05 Mil (As of Jun. 2023)

View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics Common Stock?

Aprinoia Therapeutics's quarterly common stock increased from Jun. 2022 ($0.00 Mil) to Dec. 2022 ($3.86 Mil) and increased from Dec. 2022 ($3.86 Mil) to Jun. 2023 ($4.05 Mil).

Aprinoia Therapeutics's annual common stock increased from . 20 ($0.00 Mil) to Dec. 2021 ($3.84 Mil) and increased from Dec. 2021 ($3.84 Mil) to Dec. 2022 ($3.86 Mil).

Aprinoia Therapeutics Common Stock Historical Data

The historical data trend for Aprinoia Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Common Stock Chart

Aprinoia Therapeutics Annual Data

Trend

Dec21

Dec22

Common Stock

3.84

3.86

Aprinoia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
Common Stock	3.84	-	3.86	4.05

Aprinoia Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines